Article

Rudolph Navari on Preventing CINV With Olanzapine

Author(s):

Rudolph Navari, discusses a study of olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy.

Rudolph Navari, director, Cancer Care Program in Central and South America, World Health Organization, professor of medicine, Indiana University School of Medicine-South Bend, discusses a study of olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Building long-term trust with providers can help patients with MPNs feel supported, encourage them to speak up and navigate care with confidence.
The field of radiation oncology has advanced in brain cancer treatment with precise therapeutic approaches including proton and carbon therapy.
Image of Dr. Doug
Image of doctor.
Image of Dr. Kelly
Image of Dr. Boffa.
Immune Therapy Expands Melanoma Treatment to More Patients
Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment plan.
image of doctor D'Sa
Image of Dr. Eng.